EDNRA and breast carcinoma: Conversely, breast cancer–injected mice treated with the ETAR blocker atrasentan showed a significant reduction in LV end-systolic volume/TL, LV internal diameter diastole/TL, and LV internal diameter systole/TL (Figures 1G, 1I, and 1J) compared with breast cancer–injected mice administered vehicle.